Abstract
Background and purpose:
Meningiomas are the most common primary tumours of the central nervous system. This study aimed to provide comprehensive nationwide estimates on the incidence, prevalence and prognostic impact of meningioma diagnosis in the Netherlands.
Methods:
Adult patients diagnosed with meningioma in 2000–2019 were selected from the Dutch Brain Tumour Registry (DBTR), part of the Netherlands Cancer Registry (NCR). Time trends in age-adjusted incidence and prevalence rates were evaluated using the estimated annual percentage change (EAPC). Relative survival rates were calculated using the Pohar Perme estimator. Case completeness of the DBTR/NCR was estimated through record linkage with one of the Dutch neuro-oncology centres.
Results:
From a total of 23,454 cases of meningioma, 11,306 (48.2%) were histologically confirmed and 12,148 (51.8%) were radiological diagnoses. Over time, the incidence of diagnosis increased from 46.9 per 1,000,000 inhabitants (European Standardized Rate [ESR]) to 107.3 (EAPC 4.7%, p < 0.01), with an increase in the incidence of radiological diagnoses from 14.0 to 70.2 per 1,000,000 ESR (EAPC 9.1%, p < 0.01). The prevalence of meningioma was estimated at 1012/1,000,000 on 1 January 2020, with almost 17,800 individuals having had a diagnosis of meningioma. Relative survival rate at 10 years for grade 1 meningiomas was 91.0% (95% confidence interval [CI] 89.4%–92.3%), 71.3% (95% CI 66.8%–75.2%) for grade 2 meningiomas and 36.4% (95% CI 27.3%–45.6%) for grade 3 meningiomas. Local case completeness was estimated at 97.6% for histologically confirmed meningiomas and 84.5% for radiological diagnoses.
European Journal of NeurologyWith a near-complete registry, meningioma prevalence was estimated at over 1000 per 1,000,000 inhabitants.
Original language | English |
---|---|
Pages (from-to) | 3244-3255 |
Number of pages | 12 |
Journal | European Journal of Neurology |
Volume | 30 |
Issue number | 10 |
DOIs | |
Publication status | Published - Oct 2023 |
Bibliographical note
Funding Information:The authors thank the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for the Dutch Brain Tumour Registry (DBTR) and the Netherlands Cancer Registry (NCR).
Publisher Copyright:
© 2023 European Academy of Neurology.